Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 601–700 of 1,082
Advances in immunotherapy for colorectal cancer: a review
Golshani, G., & Zhang, Y. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820917527 · Cited by 236
Haffner, M. C., Kronberger, I. E., Ross, J. S., Sheehan, C. E., Zitt, M., Mühlmann, G., Öfner, D., Zelger, B., Ensinger, C., Yang, X. J., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.06.003 · Cited by 236
Hurwitz, H. I., Tebbutt, N. C., Kabbinavar, F., Giantonio, B. J., Guan, Z.-Z., Mitchell, L., Waterkamp, D., & Tabernero, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0107 · Cited by 236
Self-citationRole of shear-stress-induced VEGF expression in endothelial cell survival
dela Paz, N. G., Walshe, T. E., Leach, L. L., Saint-Geniez, M., & D'Amore, P. A. (2012) · Journal of Cell Science · doi:10.1242/jcs.084301 · Cited by 236
Tang, P. A., Bentzen, S. M., Chen, E. X., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1935 · Cited by 236
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
Saman, H., Raza, S. S., Uddin, S., & Rasul, K. (2020) · Cancers · doi:10.3390/cancers12051172 · Cited by 232
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
Gallagher, D. J., & Kemeny, N. (2010) · Oncology · doi:10.1159/000315730 · Cited by 235
Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Dulak, J., & Jozkowicz, A. (2005) · Current Cancer Drug Targets · doi:10.2174/156800905774932824 · Cited by 235
Bhat, A. A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12295 · Cited by 229
Santini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
Ranpura, V., Pulipati, B., Chu, D., Zhu, X., & Wu, S. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.25 · Cited by 235
Targeting tumor angiogenesis with histone deacetylase inhibitors
Ellis, L., Hammers, H., & Pili, R. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.012 · Cited by 232
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
Pinter, M., Scheiner, B., & Peck-Radosavljevic, M. (2021) · Gut · doi:10.1136/gutjnl-2020-321702 · Cited by 233
Carbajo-Pescador, S., Ordoñez, R., Benet, M., Jover, R., García-Palomo, A., Mauriz, J. L., & González-Gallego, J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.285 · Cited by 233
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
Hur, H., Ko, Y. T., Min, B. S., Kim, K. S., Choi, J. S., Sohn, S. K., Cho, C. H., Ko, H. K., Lee, J. T., & Kim, N. K. (2009) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.04.013 · Cited by 233
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233
Reardon, D. A., & Wen, P. Y. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-152 · Cited by 231
Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9237 · Cited by 232
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Antiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Hobbs, B. P., Sargent, D. J., & Carlin, B. P. (2012) · Bayesian Analysis · doi:10.1214/12-ba722 · Cited by 230
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 230
Matsumura, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.05.008 · Cited by 230
Los, M., Roodhart, J. M. L., & Voest, E. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-443 · Cited by 229
for the Italian Society of Locoregional Therapies in Oncology (SITILO), Cosimelli, M., Golfieri, R., Cagol, P. P., Carpanese, L., Sciuto, R., Maini, C. L., Mancini, R., Sperduti, I., Pizzi, G., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605770 · Cited by 228
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Multi‐targeted therapy by curcumin: how spicy is it?
Goel, A., Jhurani, S., & Aggarwal, B. B. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700354 · Cited by 228
Folprecht, G., Seymour, M. T., Saltz, L., Douillard, J.-Y., Hecker, H., Stephens, R. J., Maughan, T. S., Van Cutsem, E., Rougier, P., Mitry, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0509 · Cited by 228
Thomas, A. L., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
Varey, A. H. R., Rennel, E. S., Qiu, Y., Bevan, H. S., Perrin, R. M., Raffy, S., Dixon, A. R., Paraskeva, C., Zaccheo, O., Hassan, A. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604308 · Cited by 226
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Friedlander, M., Hancock, K. C., Rischin, D., Messing, M. J., Stringer, C. A., Matthys, G. M., Ma, B., Hodge, J. P., & Lager, J. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.033 · Cited by 226
Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer
Temple, L. K. F., Hsieh, L., Wong, W. D., Saltz, L., & Schrag, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.218 · Cited by 227
Spigel, D. R., Townley, P. M., Waterhouse, D. M., Fang, L., Adiguzel, I., Huang, J. E., Karlin, D. A., Faoro, L., Scappaticci, F. A., & Socinski, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3423 · Cited by 226
Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 224
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Hu, X., Cao, J., Hu, W., Wu, C., Pan, Y., Cai, L., Tong, Z., Wang, S., Li, J., Wang, Z., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-820 · Cited by 225
DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
Li, J.-L., Sainson, R. C. A., Oon, C. E., Turley, H., Leek, R., Sheldon, H., Bridges, E., Shi, W., Snell, C., Bowden, E. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1704 · Cited by 224
Hurwitz, H. I., Saltz, L. B., Van Cutsem, E., Cassidy, J., Wiedemann, J., Sirzén, F., Lyman, G. H., & Rohr, U.-P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3220 · Cited by 226
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1317 · Cited by 226
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
Lee, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3751 · Cited by 224
A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
Kim, L. A., & D'Amore, P. A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.006 · Cited by 220
Forty-Year Journey of Angiogenesis Translational Research
Cao, Y., Arbiser, J., D’Amato, R. J., D’Amore, P. A., Ingber, D. E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 223
A Peptoid “Antibody Surrogate” That Antagonizes VEGF Receptor 2 Activity
Udugamasooriya, D. G., Dineen, S. P., Brekken, R. A., & Kodadek, T. (2008) · Journal of the American Chemical Society · doi:10.1021/ja711193x · Cited by 222
ROSENFELD, P., SCHWARTZ, S., BLUMENKRANZ, M., MILLER, J., HALLER, J., REIMANN, J., GREENE, W., & SHAMS, N. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.01.043 · Cited by 223
Kemeny, N., Jarnagin, W., Paty, P., Gönen, M., Schwartz, L., Morse, M., Leonard, G., D’Angelica, M., DeMatteo, R., Blumgart, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.100 · Cited by 223
Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity
Hwang, C. K., Hubbard, G. B., Hutchinson, A. K., & Lambert, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.12.017 · Cited by 223
Surgical Therapy for Colorectal Metastases to the Liver
Pawlik, T. M., & Choti, M. A. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-006-0061-3 · Cited by 221
Soultati, A., Mountzios, G., Avgerinou, C., Papaxoinis, G., Pectasides, D., Dimopoulos, M.-A., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.002 · Cited by 221
Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1542 · Cited by 221
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., & Harris, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9501 · Cited by 221
Chae, S.-S., Paik, J.-H., Furneaux, H., & Hla, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422716 · Cited by 220
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
Manzano, R. P. A., Peyman, G. A., Khan, P., Carvounis, P. E., Kivilcim, M., Ren, M., Lake, J. C., & Chevez-Barrios, P. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.107912 · Cited by 220
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., Atkins, M. B., Leming, P., & Kirkwood, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1529 · Cited by 221
Dahlberg, S. E., Sandler, A. B., Brahmer, J. R., Schiller, J. H., & Johnson, D. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4482 · Cited by 223
Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer
Saif, M. W., Elfiky, A., & Salem, R. R. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9337-9 · Cited by 219
Grothey, A., Fakih, M., & Tabernero, J. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 220
Antiangiogenic Therapy for Cancer: An Update
Al‐Husein, B., Abdalla, M., Trepte, M., DeRemer, D. L., & Somanath, P. R. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1147 · Cited by 216
Wakabayashi, T., Oshima, Y., Sakaguchi, H., Ikuno, Y., Miki, A., Gomi, F., Otori, Y., Kamei, M., Kusaka, S., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.026 · Cited by 217
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 217
Changing Patterns of Bone and Brain Metastases in Patients with Colorectal Cancer
Sundermeyer, M. L., Meropol, N. J., Rogatko, A., Wang, H., & Cohen, S. J. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.n.022 · Cited by 216
Nakamura, K., Taguchi, E., Miura, T., Yamamoto, A., Takahashi, K., Bichat, F., Guilbaud, N., Hasegawa, K., Kubo, K., Fujiwara, Y., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4290 · Cited by 207
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt523 · Cited by 219
FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer
Cohen, M. H., Gootenberg, J., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-356 · Cited by 217
Vascular Complications of Cancer Chemotherapy
Cameron, A. C., Touyz, R. M., & Lang, N. N. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.12.023 · Cited by 214
Ranibizumab in neovascular age-related macular degeneration
Eng, K. T., & Kertes, P. J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.451 · Cited by 216
Tumor-derived exosomes in cancer progression and treatment failure
Yu, S., Cao, H., Shen, B., & Feng, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6022 · Cited by 216
McLeod, H. L., Sargent, D. J., Marsh, S., Green, E. M., King, C. R., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Thibodeau, S. N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.7943 · Cited by 216
Transcriptional network governing the angiogenic switch in human pancreatic cancer
Abdollahi, A., Schwager, C., Kleeff, J., Esposito, I., Domhan, S., Peschke, P., Hauser, K., Hahnfeldt, P., Hlatky, L., Debus, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705505104 · Cited by 215
Recent Therapeutic Advances in the Treatment of Colorectal Cancer
Ciombor, K. K., Wu, C., & Goldberg, R. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051513-102539 · Cited by 215
Beer, A. J., Grosu, A.-L., Carlsen, J., Kolk, A., Sarbia, M., Stangier, I., Watzlowik, P., Wester, H.-J., Haubner, R., & Schwaiger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0528 · Cited by 217
Anti-Angiogenics: Current Situation and Future Perspectives
Zirlik, K., & Duyster, J. (2018) · Oncology Research and Treatment · doi:10.1159/000488087 · Cited by 216
FDA Drug Approval Summary: Panitumumab (Vectibix™)
Giusti, R. M., Shastri, K. A., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-577 · Cited by 214
Tufail, A., Patel, P. J., Egan, C., Hykin, P., da Cruz, L., Gregor, Z., Dowler, J., Majid, M. A., Bailey, C., Mohamed, Q., et al. (2010) · BMJ · doi:10.1136/bmj.c2459 · Cited by 213
Survival comparison between glioblastoma multiforme and other incurable cancers
Tran, B., & Rosenthal, M. A. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.09.004 · Cited by 210
Niche-to-niche migration of bone-marrow-derived cells
Kaplan, R. N., Psaila, B., & Lyden, D. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.12.003 · Cited by 212
Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
O'Connell, M. J., Campbell, M. E., Goldberg, R. M., Grothey, A., Seitz, J.-F., Benedetti, J. K., André, T., Haller, D. G., & Sargent, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8261 · Cited by 213
Schmoll, H.-J., Cunningham, D., Sobrero, A., Karapetis, C. S., Rougier, P., Koski, S. L., Kocakova, I., Bondarenko, I., Bodoky, G., Mainwaring, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.5355 · Cited by 213
Angiogenic inhibitors: a new therapeutic strategy in oncology
Gasparini, G., Longo, R., Toi, M., & Ferrara, N. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0342 · Cited by 212
Self-citationTol, J., Koopman, M., Rodenburg, C. J., Cats, A., Creemers, G. J., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., Mol, L., Antonini, N. F., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm607 · Cited by 212
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
Lee, S. H., Jeong, D., Han, Y.-S., & Baek, M. J. (2015) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2015.89.1.1 · Cited by 210
Imaging of integrin αvβ3 expression
Beer, A. J., & Schwaiger, M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9158-3 · Cited by 211
Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer
Tsukamoto, S., Ishikawa, T., Iida, S., Ishiguro, M., Mogushi, K., Mizushima, H., Uetake, H., Tanaka, H., & Sugihara, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2884 · Cited by 210
Díaz-Rubio, E., Gómez-España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., Rivera, F., Safont, M. J., Martínez de Prado, P., Gallén, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0249 · Cited by 210
Ebos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
Tol, J., Dijkstra, J. R., Klomp, M., Teerenstra, S., Dommerholt, M., Vink-Börger, M. E., van Cleef, P. H., van Krieken, J. H., Punt, C. J. A., & Nagtegaal, I. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.03.036 · Cited by 210
Del Rio, M., Molina, F., Bascoul-Mollevi, C., Copois, V., Bibeau, F., Chalbos, P., Bareil, C., Kramar, A., Salvetat, N., Fraslon, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.4187 · Cited by 210
Cancer-Associated Thrombosis: An Overview
Elyamany, G., Alzahrani, A. M., & Bukhary, E. (2014) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s18991 · Cited by 209
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma
Pang, R., & Poon, R. T. P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.01.008 · Cited by 210
Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A., Townsend, A. R., Wrin, J. W., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 209
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Albert, D. H., Tapang, P., Magoc, T. J., Pease, L. J., Reuter, D. R., Wei, R.-Q., Li, J., Guo, J., Bousquet, P. F., Ghoreishi-Haack, N. S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0410 · Cited by 207
Patel, B. B., Sengupta, R., Qazi, S., Vachhani, H., Yu, Y., Rishi, A. K., & Majumdar, A. P. N. (2008) · International Journal of Cancer · doi:10.1002/ijc.23097 · Cited by 208
CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis
Jiang, T., Zhuang, J., Duan, H., Luo, Y., Zeng, Q., Fan, K., Yan, H., Lu, D., Ye, Z., Hao, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406108 · Cited by 209
Adam, R., Aloia, T., Lévi, F., Wicherts, D. A., de Haas, R. J., Paule, B., Bralet, M.-P., Bouchahda, M., Machover, D., Ducreux, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8126 · Cited by 208
van der Bij, G. J., Oosterling, S. J., Beelen, R. H. J., Meijer, S., Coffey, J. C., & van Egmond, M. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a3ddbd · Cited by 208
Roland, C. L., Lynn, K. D., Toombs, J. E., Dineen, S. P., Udugamasooriya, D. G., & Brekken, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007669 · Cited by 207
Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo
Willmann, J. K., Lutz, A. M., Paulmurugan, R., Patel, M. R., Chu, P., Rosenberg, J., & Gambhir, S. S. (2008) · Radiology · doi:10.1148/radiol.2483072231 · Cited by 207
Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., & Benghozi, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.005 · Cited by 205
Tugues, S., Koch, S., Gualandi, L., Li, X., & Claesson-Welsh, L. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.004 · Cited by 205
Gender Disparities in Metastatic Colorectal Cancer Survival
Hendifar, A., Yang, D., Lenz, F., Lurje, G., Pohl, A., Lenz, C., Ning, Y., Zhang, W., & Lenz, H.-J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0877 · Cited by 206
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.